Indivior | Company Profile
Company Directory for Indivior
Indivior
Overview
Indivior PLC is a global pharmaceutical company dedicated to treating opioid use disorder (OUD) and related conditions. Established in December 2014 as a spin-off from Reckitt Benckiser Group PLC, it is publicly traded on the London Stock Exchange. The company aims to address the opioid crisis by providing access to evidence-based treatments that can significantly improve the lives of those affected.
Core products include Suboxone, a combination of buprenorphine and naloxone, Sublocade, a monthly injectable formulation, and Opvee, a naloxone product for emergency overdose response. Indivior is also developing INDV-6001, a long-acting injectable. The company engages with healthcare providers, government agencies, and patient advocacy groups to promote awareness and education about addiction as a chronic disease.
Basic Information
| Industry | pharmaceuticals |
|---|---|
| Founded | 2014 |
| Revenue | 1.2B |
| Headquarters | 10710 Midlothian Tpke, Richmond, Virginia, United States, 23235-4722 |
| Languages | English, German, Spanish, French, Italian, Portuguese, Chinese |
Contact Details
- Phone: +1 804-379-1090
- Website: indivior.com
- LinkedIn: linkedin.com/company/indivior
Key Focus Areas & Initiatives
- Opioid use disorder & rescue medications
- Biotechnology: pharmaceutical preparations
- Health care
- Pharmaceutical manufacturing
- Global healthcare
- Naloxone
- Drug regulation
- Addiction recovery science
- Pharmaceutical innovation
- Medical treatment
- R&D investment
- Drug patents
- Treatment adherence
- Pharmaceutical development
- Sublocade
- Healthcare providers
- Comprehensive addiction care
- Recovery care
- Medication compliance
- Medications for addiction
- Healthcare innovation
- Opioid dependence
- Generic competition
- Health policy
- Mental health
- Opioid addiction
- Opioid treatment access
- Global market
- Medication safety
- Injectable buprenorphine
- Mental health services
- Suboxone
- Addiction stigma reduction
- Evidence-based medicine
- Opioid epidemic response
- Healthcare access
- Medical and diagnostic laboratories
- Treatment innovation
- Financial reporting
- Recovery support
- Addiction science
- Addiction therapy
- Public health emergency
- Pharmacotherapy
- Healthcare advocacy
- Mental health treatment
- Opioid overdose treatment
- Opioid dependence management
- Opioid crisis
- Addiction treatment
- Medication-assisted treatment
- Drug development
- Patient outcomes
- Biopharmaceutical
- Long-acting buprenorphine
- Clinical research
- Substance use disorder therapies
- Data analytics
- Medical therapies
- Medical research
- Substance use disorder
- Extended release injection
- Patient safety
- Therapeutic areas
- Fentanyl
- Drug approval
- Patient-centered care
- Long-acting injectable
- Opioid overdose
- Corporate governance
- Ethical compliance
- Biopharmaceuticals
- Community engagement
- Responsibility initiatives
- Patient monitoring
- Regulatory affairs
- Corporate integrity
- Pipeline management
- Substance use prevention
- Mental illness treatment
- Research and development
- Sustainability in healthcare
- Transparency program
- Health system partnerships
- Corporate collaborations
- Stakeholder engagement
- Investor relations
- Social responsibility
- Global health initiatives
- Patient education
- Integrity and compliance
- B2B
- Manufacturing
- Distribution
- Health, wellness & fitness
- Medical
- Hospital & health care
- Medical & diagnostic laboratories
- Medical practice
- Mechanical or industrial engineering
Technologies Used
- CSC Corporate Domains
- Google Tag Manager
- Microsoft Office 365
- Mobile Friendly
- Outlook
- Rackspace MailGun
- React
- Remote
- Salesforce
- Typekit
- Workday Recruit